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Summary Points
• In high-income countries, pneumococcal conjugate vaccines induce strong herd protec-
tion that leads to near elimination of vaccine-type disease in vaccinated and
unvaccinated alike.
• In settings with minimal exposure to pneumococcal vaccine types, individual protection
from pneumococcal conjugate vaccine (PCV) is rarely required, and the majority of dis-
ease episodes are prevented by controlling vaccine-type transmission.
• Following the control of pneumococcal vaccine-type disease and colonisation through
vaccination, a PCV schedule with a single priming and a booster dose may be sufficient
to sustain that control at reduced costs and should be evaluated.
Introduction
The most efficient use of limited health resources is an important principle of public health pol-
icy. For vaccine policy, this means balancing health, economic, and sociologic considerations
to employ the best vaccine products and optimal schedules. However, the optimal schedule for
vaccine introduction might not be optimal once indirect vaccine effects are established in the
community. Persisting with dosing schedules that aim at the direct protection of individuals in
settings where the additional benefit of direct protection is limited through the presence of
herd effects may prevent inclusion of additional vaccines into the vaccination programme and
consume resources that could be spent more efficiently elsewhere. Here we discuss how the
substantial decline in transmission of strains targeted by the vaccine (vaccine-type pneumococ-
ci) in high-income countries following pneumococcal conjugate vaccine (PCV) introduction
presents an opportunity to investigate if the number of PCV doses in the infant schedule could
be reduced without compromising its public health benefit.
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Current PCV Schedules
A seven-valent PCV (PCV7), providing protection against the most common serotypes causing
pneumococcal disease in high-income countries, was licensed in the United States and recom-
mended for use in the infant immunisation schedule in 2000. The licensing schedule consisted
of three priming doses at 2, 4, and 6 months of age and a booster dose at 12 to 15 months (3+1
schedule). Subsequent PCV trials demonstrated efficacy when administered without the boost-
er dose (3+0 schedule) and aligned with the World Health Organization’s (WHO) Expanded
Programme on Immunization (EPI) schedule [1]. Hence, the 3+0 schedule is adopted mostly
by low- and middle-income countries that tailor their vaccination programmes to the
EPI schedule.
In the United Kingdom, PCV7 was introduced with a two-dose primary series, at 2 and 4
months of age, and a booster dose at 13 months (2+1 schedule). This was adopted on the
grounds of programmatic simplicity, reduced costs, and generally similar immunogenicity to
the 3+1 schedule [2]. Motivated by similar considerations, including the need to create space
for other vaccines in a crowded primary series, other high-income countries have adopted a
2+1 PCV schedule. Disease surveillance has demonstrated that 2+1 and 3+1 schedules both in-
duce strong indirect protection reducing the incidence of vaccine-type colonization and conse-
quent invasive pneumococcal disease (IPD) almost to the point of elimination within the
community. Hence, the marginal superiority of the 3+1 schedule for direct protection of in-
fants is scarcely measurable at the population level [3].
Considerations for a Reduced PCV Schedule
As the strong herd effects that are induced by both a 3+1 and a 2+1 schedule resulted in a simi-
lar impact on IPD, the potential for further reduction of the primary series to a single dose
(1+1) should now be assessed for settings with a mature vaccination programme, where vac-
cine-type carriage is largely eliminated in the community, high vaccine coverage of both doses
can be assured, and careful monitoring is feasible. Other two-dose schedules may be similarly
effective; however, we focus our argument on the simplest programmatic option, i.e., the re-
moval of an existing dose. A schedule with fewer doses in the primary schedule could substan-
tially reduce the costs of pneumococcal immunisation and make space for other vaccines in
crowded infant vaccination programmes in high-income countries. A single dose in infancy in-
duces lower antibody responses and provides less protection against disease and carriage than
a two- or three-dose primary series [4]. In mature vaccine programmes, however, individual
protection is rarely required because the probability of exposure to vaccine-type infection is
low. For example, 8 years after the introduction of PCV7 in the US, the relative prevalence of
vaccine-type pneumococcal carriage among children in Massachusetts fell from 36% to 2%,
and vaccine-type IPD was virtually eliminated [3,5].
The success of a 1+1 PCV schedule is contingent on its ability to sustain established herd
protection, which, in turn, depends on the relative contribution made by different doses in the
schedule to reducing vaccine-type transmission. The magnitude of reduced transmission for
each serotype, and consequently the magnitude of serotype-specific herd protection against
pneumococcal disease, is a result of several factors, including the vaccine efficacy against car-
riage acquisition, the duration of vaccine protection, the prevalence of carriage, and the num-
ber of contacts of individuals. In high-income settings, children aged 1–4 years have the
highest carriage prevalence and have high contact frequencies implicating them as strong driv-
ers of pneumococcal transmission. Protecting this age group by vaccination, therefore, has a
disproportionately powerful influence on herd protection. Given the relatively lower contact
frequencies of infants, protection against carriage in the first year of life is less likely to
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contribute to overall herd protection. Hence, the key epidemiologic question is, would a re-
duced primary compromise the present levels of herd protection by reducing the vaccine effica-
cy of the booster dose against acquisition of carriage?
The relative impact of a booster dose on carriage following a reduced primary series of one
versus two doses has not been studied. Among Israeli toddlers, acquisition rates for pneumo-
coccal carriage and serotype-specific anticapsular immunoglobulin G (IgG) were compared
both before and after receipt of a booster dose at 12 months of age between groups of children
who were administered two or three primary doses [6]. After priming with two instead of three
doses, vaccine-type acquisition rates were lower in the 18 months post booster, and antibody
concentrations at 1 and 7 months after boosting were similar. In the UK, antibody levels after
the PCV7 booster were significantly higher for serotypes 4, 9V, and 14 in children primed with
two instead of three doses, but lower for 6B and 23F [7]. By extension, further reducing the pri-
mary series to a single PCV dose would not necessarily impair the postbooster immune re-
sponse, but this remains to be established. Notably, the total quantity of antigen used for
priming with Neisseria meningitis type C conjugate vaccine is negatively correlated with the
magnitude of the booster response [8].
Assuming that a 1+1 PCV schedule is found to maintain herd protection through the con-
trol of vaccine-type carriage, the optimum timing of the programmatic switch to a reduced pri-
mary series would need careful consideration. Although there would be little risk of additional
IPD cases associated with a reduced primary series once vaccine-type pneumococcal disease
has been eliminated in the population, the schedule switch may be cost-effective before that.
An example of this kind of reasoning is given by the decision in the UK not to expand the indi-
cation for PCVs to adults at increased risk for pneumococcal disease although there was residu-
al circulation of vaccine types in the population in 2012 [9]. Other recent policy decisions
illustrate the acceptance and importance of incorporating herd protection in the evaluation of
vaccine programmes. Maintaining herd protection without increasing programmatic costs was
the defining factor in the decision of the UK to move the second dose of the three-dose mono-
valent meningococcal C conjugate vaccine schedule from infancy to adolescence, when carriage
prevalence is likely to be highest [10]. A shift in vaccination programmes towards increasing
reliance on indirect protection requires informing and educating both vaccinators and vacci-
nees on the associated benefits and risks. This needs to include discussions on whether any in-
crease in individual risk and associated equity issues is acceptable if this frees resources that
can otherwise be used more effectively to benefit public health. These have been central points
in the recent discussion among the Advisory Committee on Immunization Practices in the US
on a potential reduction of a four-dose PCV schedule to a three-dose schedule [11].
TheWay Forward
Before the implications of a policy shift to a reduced dose PCV schedule can be weighed objec-
tively, key evidence gaps need to be filled. These include (1) the relative impact of a one- or
two-dose primary series on the vaccine effectiveness of the booster dose against carriage—mea-
sured in terms of magnitude and duration, (2) the relative impact of one or two primary doses
on protection against disease before the booster, and (3) the impact of age of administration of
a single primary dose on (1) and (2). Given the virtual elimination of vaccine-type carriage in
high-income countries that have introduced PCVs, the predominant question (1) is intractable
in these settings.
Correlates of protection (CoPs) offer a potential alternative to the assessment of carriage as
a study end point. Higher valent PCVs have been licensed based on noninferiority immunoge-
nicity studies using an aggregated threshold of 0.35 μg/mL IgG antibody as a CoP against IPD,
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although this threshold likely is an oversimplification [4]. Serum immunogenicity as a CoP
against pneumococcal carriage is less well established. As mucosal immunity is central to pro-
tecting against carriage acquisition and reducing density of colonization, the measurement of
systemic antibodies is recognised as a proxy for what is likely occurring at the mucosal surface.
The impact of PCV at the mucosal level is dependent on both the number and timing of PCV
doses [12]. A putative protective threshold of 4–5 μg/mL IgG antibody has been suggested for
antibodies acquired by PCV immunisation or natural infection [13], similar to the threshold
found for Haemophilus influenzae type B (Hib) conjugate vaccine protection against Hib colo-
nisation. However, the reverse cumulative distribution of pooled antibody concentration [4] in
combination with an observed vaccine efficacy against colonisation of 40%–50% suggests that
2 μg/mL IgG antibody may suffice as a protective threshold for colonisation. If a 1+1 schedule
is found to induce inferior postbooster protective serum antibody concentrations against colo-
nisation transmission, dynamic models can help to assess the effect of reduced herd protection
on the risk for pneumococcal disease in the community. Also, rigorous postimplementation
surveillance of pneumococcal colonisation and disease, in particular among risk groups, will be
essential to immediately detect a potential resurgence of vaccine-type circulation in
the community.
Currently, the conditions for regimen simplification, and therefore the potential benefits,
are limited to high-income countries. The additional epidemiologic and programmatic consid-
erations around a two-dose PCV schedule in low-income countries are complex and beyond
the scope of this commentary. However, successful implementation in high-income countries
would support the evidence base for a reduced PCV series and may incentivise the evaluation
of alternative PCV schedules in low-income countries that could eventually lead to a much wel-
comed reduction in the costs of the PCV programme.
In conclusion, evidence from high-income countries, which have accumulated up to 15
years of routine PCV use, consistently demonstrates that most vaccine-type pneumococcal dis-
ease has almost been eliminated among both unvaccinated and vaccinated children [3]. The
changing epidemiology of the pneumococcus now invites us to consider whether the successful
elimination of vaccine-type disease could be retained in a childhood immunisation schedule
with fewer PCV doses. There is a compelling argument to now generate the evidence needed to
evaluate whether such a change in the PCV schedule is beneficial.
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